Inovio Pharmaceuticals (INO) has been beaten down lately with too much selling pressure. While the stock has lost 11.4% over the past four weeks, there is light at the end of the tunnel as it is now ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Inovio Pharmaceuticals Inc. INO rallied 9.94% to $1.77 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 0 ...

Inovio Pharmaceuticals, Inc.’s INO share price has surged by 10.67%, which has investors questioning if this is right time to sell.

Shares of Inovio Pharmaceuticals Inc. INO advanced 1.90% to $1.61 Friday, on what proved to be an all-around positive trading ...

CEO Jacqui Shea highlighted that Inovio remains committed to transforming into a commercial-stage company, with a primary focus on advancing INO-3107, a DNA medicine for recurrent respiratory ...

Inovio Pharmaceuticals Inc (NASDAQ:INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA submission for INO 3,107.